Youn H Kim

Clinical Trials

• Not Recruiting Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
• Recruiting Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing
• Not Recruiting A Study for Patients With Relapsed Cutaneous T-Cell Lymphoma
• Recruiting Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level
• Not Recruiting Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.
• Recruiting Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
• Recruiting Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
• Recruiting Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
• Recruiting Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
• Recruiting Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
• Not Recruiting An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
• Not Recruiting Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides
• Not Recruiting A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
• Not Recruiting Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
• Not Recruiting Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma
• Not Recruiting A Phase II Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease
• Not Recruiting Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A
• Not Recruiting Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma
• Not Recruiting Clinical Trial of PXD101 in Patients With T-Cell Lymphomas
• Not Recruiting Phase I/II CPG 7909 + Local XRT in Recurrent Low-Grade Lymphomas
• Not Recruiting A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma
• Not Recruiting Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome
• Not Recruiting Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
• Not Recruiting Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
• Not Recruiting Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma
• Not Recruiting Phase II Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides
• Not Recruiting Forodesine in the Treatment of Cutaneous T-Cell Lymphoma
• Recruiting A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma